The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2009
Evidence of protective effect of BCG vaccination in persons at low risk of tuberculosis in Nordic countries.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Brantsaeter A B, Romanus V, Andersen P H, Heldal E
Аннотация
SETTING: Norway, Sweden, Denmark and Finland have low incidence rates (IRs) of tuberculosis (TB) but the use of bacille Calmette-Guérin (BCG) vaccination has varied.
OBJECTIVE: To assess if different IRs among persons at low risk in the four countries could be related to the different use of BCG vaccination, and to estimate the number of adolescent BCG vaccinations needed to prevent one case of TB in Norway.
DESIGN: The study period was 1996-2005. In part A, IRs for cases classified as 'born in country/national' in the EuroTB database in all four countries were calculated. In part B, the IRs among persons born in Norway and Sweden with two parents from low-incidence countries were calculated for cases registered in the respective national TB registers. In both parts, IRs and IR ratios among 0-14-year-olds and 15-29-year-olds were compared and related to different BCG vaccination policies.
RESULTS AND CONCLUSIONS: Our results are consistent with a protective effect of newborn BCG vaccination in native-born 0-14-year-olds in Finland, and of adolescent BCG vaccination in 15-29-year-olds in Norway. The Norwegian BCG vaccination programme conferred 61-64% protection to 15-29-year-olds; however, 21699-25125 vaccinations were needed to prevent one case.
OBJECTIVE: To assess if different IRs among persons at low risk in the four countries could be related to the different use of BCG vaccination, and to estimate the number of adolescent BCG vaccinations needed to prevent one case of TB in Norway.
DESIGN: The study period was 1996-2005. In part A, IRs for cases classified as 'born in country/national' in the EuroTB database in all four countries were calculated. In part B, the IRs among persons born in Norway and Sweden with two parents from low-incidence countries were calculated for cases registered in the respective national TB registers. In both parts, IRs and IR ratios among 0-14-year-olds and 15-29-year-olds were compared and related to different BCG vaccination policies.
RESULTS AND CONCLUSIONS: Our results are consistent with a protective effect of newborn BCG vaccination in native-born 0-14-year-olds in Finland, and of adolescent BCG vaccination in 15-29-year-olds in Norway. The Norwegian BCG vaccination programme conferred 61-64% protection to 15-29-year-olds; however, 21699-25125 vaccinations were needed to prevent one case.